ADAMTS12 and gastric cancer: Jiang et al. (12) reported that ADAMTS12 increases resistance to oxaliplatin treatment in gastric cancer cells by affecting the MAPK/VEGF pathway and is connected with vascular abnormalities, poor survival results, and chemotherapy resistance in gastric cancer patients.